Sign Up
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Medical Update Online > All Medical News > Oncology > NICE (UK) terminated appraisal for Tevimbra (tislelizumab) in combination for untreated advanced non-small-cell lung cancer – BeiGene

NICE (UK) terminated appraisal for Tevimbra (tislelizumab) in combination for untreated advanced non-small-cell lung cancer – BeiGene

Written by | 22 Jul 2025 | Oncology

NICE is unable to make a recommendation on tislelizumab (Tevimbra) in combination for untreated advanced non-small-cell lung cancer in adults.

This is because the company did not provide an evidence submission.

The company has confirmed that it does not intend to make a submission for the appraisal because the technology will not be launched in the UK for this indication.

Newsletter Icon

Register for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Sign Up

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.